Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

AIM: To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. METHODS: Safety data from 14 trials (8–104‐week durations) were analysed by treatment (alirocumab or placebo/ezetimibe control) and diabetes status (ye...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabet Med
Main Authors: Leiter, L. A., Tinahones, F. J., Karalis, D. G., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., Jones, P. H.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585811/
https://ncbi.nlm.nih.gov/pubmed/30183102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.13817
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares